David Mahvi to Melanoma
This is a "connection" page, showing publications David Mahvi has written about Melanoma.
Connection Strength
0.530
-
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial. Cancer Gene Ther. 2007 Aug; 14(8):717-23.
Score: 0.214
-
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018 Oct; 67(10):1647-1658.
Score: 0.116
-
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):540-9.
Score: 0.052
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
Score: 0.048
-
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15; 22(22):4463-73.
Score: 0.045
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther. 1999 Jan-Feb; 6(1):81-8.
Score: 0.030
-
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther. 1997 May 01; 8(7):875-91.
Score: 0.027